🇨🇦·1d agoIndustry
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
Publisher
Z
Zymeworks
Canada
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ir.zymeworks.com
Leave the platform to read the original full article on the publisher site.
Source: Zymeworks
Scope: Industry
Related coverage
More related coverage
BioInvent International·17h ago
BioInvent International AB publishes Annual Report 2025
Swedish Orphan Biovitrum·18h ago
Sobi publishes Annual and Sustainability Report for 2025
Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for...
Poxel·19h ago
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Galapagos·22h ago
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen
De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibilite...